|
|||||
|
|
Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings |
|
| Authors: | Joseph Richard W. Liu Frank Xiaoqing Shillington Alicia C. Macahilig Cynthia P. Diede Scott J. Dave Vaidehi Harshaw Qing Saretsky Todd L. Pickard Alan Simon |
| Affiliation: | 1.Department of Oncology (Medical), Mayo Clinic, Jacksonville, FL, USA ;2.Merck & Co., Philadelphia, PA, USA ;3.EPI-Q, Inc., 915 Harger Rd, Suite 350, Oak Brook, IL, 60523, USA ;4.Medical Data Analytics (MDA), Parsippany, NJ, USA ;5.Merck & Co., North Wales, PA, USA ;6.Pharmacy Systems, Outcomes and Policy, College of Pharmacy, 833 South Wood Street, Chicago, IL, 60612, USA ; |
| Abstract: | Quality of Life Research - Pembrolizumab (PEMBRO) and ipilimumab?+?nivolumab (IPI?+?NIVO) are approved advanced melanoma (AM) immunotherapies. To address limited... |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |